Key Points
- Palvella Therapeutics COO Kathleen Goin sold 4,302 shares on June 17 at an average price of $110.73, generating about $476,360. After the sale, she directly owned 2,154 shares, a 66.64% reduction in her position.
- The sale was made under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance rather than tied to a specific new event.
- Palvella recently reported a wider-than-expected quarterly loss, posting earnings of ($1.20) per share versus the consensus estimate of ($0.90). Analysts currently rate the stock a “Moderate Buy” with a consensus target price of $199.53.
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) COO Kathleen Goin sold 4,302 shares of the stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $110.73, for a total value of $476,360.46. Following the sale, the chief operating officer directly owned 2,154 shares in the company, valued at $238,512.42. This represents a 66.64% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Palvella Therapeutics Price Performance
Palvella Therapeutics stock opened at $118.84 on Tuesday. The firm has a market cap of $1.70 billion, a PE ratio of -28.50 and a beta of -0.14. The stock's fifty day moving average price is $118.40 and its two-hundred day moving average price is $109.24. Palvella Therapeutics, Inc. has a one year low of $20.35 and a one year high of $151.18.
Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.90) by ($0.30). Sell-side analysts expect that Palvella Therapeutics, Inc. will post -5.26 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of research firms recently commented on PVLA. Stifel Nicolaus set a $250.00 price target on Palvella Therapeutics in a research note on Tuesday, February 24th. Mizuho increased their price objective on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 25th. HC Wainwright raised their target price on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the company a "buy" rating in a report on Tuesday, March 24th. Truist Financial set a $210.00 target price on shares of Palvella Therapeutics in a research report on Tuesday, February 24th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $240.00 price target on shares of Palvella Therapeutics in a report on Thursday, May 21st. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $199.53.
Check Out Our Latest Stock Report on PVLA
Hedge Funds Weigh In On Palvella Therapeutics
Institutional investors have recently modified their holdings of the business. First Light Asset Management LLC bought a new stake in shares of Palvella Therapeutics during the third quarter worth $33,949,000. Suvretta Capital Management LLC boosted its holdings in shares of Palvella Therapeutics by 15.1% during the 3rd quarter. Suvretta Capital Management LLC now owns 822,400 shares of the company's stock valued at $51,556,000 after acquiring an additional 107,937 shares in the last quarter. Apis Capital Advisors LLC bought a new stake in Palvella Therapeutics during the 3rd quarter worth $627,000. Jennison Associates LLC raised its position in Palvella Therapeutics by 262.4% in the fourth quarter. Jennison Associates LLC now owns 387,483 shares of the company's stock valued at $40,558,000 after purchasing an additional 280,573 shares during the last quarter. Finally, Fred Alger Management LLC boosted its stake in shares of Palvella Therapeutics by 1,279.1% during the third quarter. Fred Alger Management LLC now owns 186,751 shares of the company's stock valued at $11,707,000 after purchasing an additional 173,209 shares in the last quarter. Institutional investors and hedge funds own 40.11% of the company's stock.
About Palvella Therapeutics
(
Get Free Report)
Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.
Palvella's pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
